PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children

Thrombosis and Haemostasis

Volumn 99, Issue 2, 2008, Pages 352-356

  Kinik, Sibel Tulgar ^a   Özbek, Namik ^a   Yuce, Muammer ^a   Yazici, Ayse Canan ^a   Verdi, Hasibe ^a   Ataç, F Belgin ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Childhood obesity; Cytokines; PAI 1 gene 4G 5G polymorphism

Indexed keywords

CYTOKINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLISM; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; OBESITY; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38949114982     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0395     Document Type: Article

References (37)

1. Winkler UH. Obesity and haemostasis. Arch Gynecol and Obstet 1997; 261: 25-29.
2. Albisetti M, Chan AKC, McCrindle BW, et al. Impaired fibrinolytic activity is present in children with dyslipidemias. Pediatr Res 2004; 55: 576-580.
3. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004; 89: 447-452.
4. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
5. Estelles A, Dalmau J, Falco C, et al. Plasma PAI-1 levels in obese children - effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-652.
6. Valle M, Gascon F, Martos R, et al. Relationship between high plasma leptin concentrations and metabolic syndrome in obese pre-pubertal children. Int J Obes 2003; 27: 13-18.
7. Glowinska B, Urban M, Koput A. Cardiovascular risk factors in children with obesity, hypertension, and diabetes: lipoprotein(a) levels and body mass index correlate with family history of cardiovascular disease. Eur J Pediatr 2002; 161: 511-518.
8. Vairaktaris E, Yiannopoulos A, Vylliotis A, et al. Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 2006; 21: 246-250 .
9. Sartori MT, Vettor R, De Pergola G, et al. Role of the 4G/5G polymorphism of PAI-1 gene promoter on PAI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost 2001; 86: 1161-1169.
10. Eriksson P, Kallin B, Van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
11. Hoffstedt J, Andersson LL, Persson L, et al. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-587.
12. Asselbergs FW, Williams SM, Hebert PR, et al. The gender-spesific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 2006; 96: 471-477.
13. Doggen CJM, Bertina RM, Cats VM, et al. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999; 82: 115-120.
14. Voros G, Maquoi E, Collen D, et al. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α coverting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta 2003; 1625: 36-42.
15. Samad F, Uysal TK, Wiesbrock SM, et al. Tumor necrosis factor α is a key component in the obesitylinked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-6907.
16. Crandall DL, Quinet EM, Morgan GA, et al. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J Clin Endocrinol Metab 1999; 84: 3222-3227.
17. 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374-1380.
18. Bundak R, Furman A, Gunoz H, et al. Body mass index references for Turkish chidren. Acta Paediatr 2006; 95: 194-198.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28, 412-419.
20. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
21. Margaglione M, Granda E, Vecchione G, et al. Plasminogen activator inhibitor -1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 1997; 17: 2082-2087.
22. Morange PE, Lijnen HR, Alessi MC, et al. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet induced obesity. Arteroscler Thromb Vasc Biol 2000; 20: 1150-1154.
23. Kinik ST, Atac FB, Verdi H, et al. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children. Clin Endocrinol 2005; 62: 607-610.
24. Akar N, Akar E, Yilmaz E, et al. Plaminogen-activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J Child Neurol 2001; 16: 294-295.
25. Balta G, Altay Ç, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002; 71: 89-93.
26. Berberoǧlu M, Evliyaoǧlu O, Adiyaman P, et al. Plasminogen activator inhibitor-1 (PAI-I) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. J Pediatr Endocrinol Metab 2006; 19: 741-748.
27. Epstein FH. Plaminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 34: 1792-1801.
28. Asplund Carlson A, Hamsten A, Wiman B, et al. Relationship between plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, inslin levels and insulin sensitivity:studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825.
29. Giltay EJ, Elbers JMH, Gooren LJG, et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women. Modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998; 18: 1716-1722.
30. Ferguson MA, Gutin B, Owens C, et al. Fat disribution and haemostatic measures in obese children. Am J Clin Nutr 1998; 67: 1136-1140.
31. Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-347.
32. Bastelica D, Mavri A, Verdier M, et al. Relationship between fibrinolytic and inflammatory parameters in human adipose tissue: Strong contribution of TNF a receptors to PAI-1 levels. Thromb Haemost 2002; 88: 481-487.
33. Skurk T, van Harmelen V, Lee YM, et al. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 2002; 34: 659-663.
34. Morange PE, Alessi MC, Verdier M, et al. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999; 19: 1361-1365.
35. 1 release by human adipose tissue is enhanced in obesity. Metab Clin Exp 2005; 54: 1546-1551.
36. 1) in obese women. Int J Obes 1997; 21: 704-707.
37. Byrne CD, Wareham NJ, Martensz ND, et al. Increased PAI-1 level and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels. Atherosclerosis 1998; 140: 45-53.